CSIMarket Company Name, Ticker, Competitors, else..
 
Design Therapeutics Inc   (NASDAQ: DSGN)
 

Design Therapeutics Inc's Suppliers Performance

DSGN's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
DSGN Costs vs Sales of Suppliers Growth

• More on DSGN Suppliers






Design Therapeutics Inc's Comment on Supply Chain


The company relies on single-source suppliers for its product candidates, which presents risks related to supply quantity, cost, and quality. In May 2023, an issue with the vial stopper used by the vendor manufacturing DT-216P1 caused a short delay in product supply for a Phase 1 clinical trial. There is only one supplier for an excipient component of DT-216P2, and establishing additional sources may be difficult or impossible on acceptable terms. All contract manufacturers and entities involved in therapeutic preparation must comply with current Good Manufacturing Practice (cGMP) regulations enforced by the FDA and comparable foreign authorities. The company depends entirely on contract manufacturers for compliance with these regulations and is subject to potential unannounced inspections. Noncompliance could result in sanctions including shutdowns, fines, or recalls.

Design Therapeutics Inc's Comment on Supply Chain


The company relies on single-source suppliers for its product candidates, which presents risks related to supply quantity, cost, and quality. In May 2023, an issue with the vial stopper used by the vendor manufacturing DT-216P1 caused a short delay in product supply for a Phase 1 clinical trial. There is only one supplier for an excipient component of DT-216P2, and establishing additional sources may be difficult or impossible on acceptable terms. All contract manufacturers and entities involved in therapeutic preparation must comply with current Good Manufacturing Practice (cGMP) regulations enforced by the FDA and comparable foreign authorities. The company depends entirely on contract manufacturers for compliance with these regulations and is subject to potential unannounced inspections. Noncompliance could result in sanctions including shutdowns, fines, or recalls.







DSGN's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Design Therapeutics Inc 776.32 0.00 -70.80 54
SUBTOTAL 0.00 0.00 0.00 -


Sources: Design Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Design Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.